beta-lapachone has been researched along with Necrosis in 9 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "beta-lapachone induced cell death in a spectrum of human carcinoma cells, including nonproliferating cells." | 7.70 | Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells. ( Li, CJ; Li, YZ; Pardee, AB; Pinto, AV, 1999) |
| "Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed." | 3.78 | An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. ( Bair, JS; Bey, EA; Boothman, DA; Dong, Y; Gao, J; Hergenrother, PJ; Huang, X; Kilgore, JA; Li, LS; Parkinson, EI; Patel, M; Wang, Y; Williams, NS, 2012) |
| "beta-lapachone induced cell death in a spectrum of human carcinoma cells, including nonproliferating cells." | 3.70 | Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells. ( Li, CJ; Li, YZ; Pardee, AB; Pinto, AV, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gerber, DE | 1 |
| Beg, MS | 1 |
| Fattah, F | 1 |
| Frankel, AE | 1 |
| Fatunde, O | 1 |
| Arriaga, Y | 1 |
| Dowell, JE | 1 |
| Bisen, A | 1 |
| Leff, RD | 1 |
| Meek, CC | 1 |
| Putnam, WC | 1 |
| Kallem, RR | 1 |
| Subramaniyan, I | 1 |
| Dong, Y | 3 |
| Bolluyt, J | 1 |
| Sarode, V | 1 |
| Luo, X | 1 |
| Xie, Y | 1 |
| Schwartz, B | 1 |
| Boothman, DA | 4 |
| Bey, EA | 3 |
| Reinicke, KE | 1 |
| Srougi, MC | 1 |
| Varnes, M | 1 |
| Anderson, VE | 1 |
| Pink, JJ | 1 |
| Li, LS | 2 |
| Patel, M | 3 |
| Cao, L | 1 |
| Moore, Z | 1 |
| Rommel, A | 1 |
| Boatman, M | 1 |
| Lewis, C | 1 |
| Euhus, DM | 1 |
| Bornmann, WG | 1 |
| Buchsbaum, DJ | 1 |
| Spitz, DR | 1 |
| Gao, J | 3 |
| Morales, J | 1 |
| Li, L | 1 |
| Fattah, FJ | 1 |
| Park, EJ | 1 |
| Min, KJ | 1 |
| Lee, TJ | 1 |
| Yoo, YH | 1 |
| Kim, YS | 1 |
| Kwon, TK | 1 |
| Dos Anjos, DO | 1 |
| Sobral Alves, ES | 1 |
| Gonçalves, VT | 1 |
| Fontes, SS | 1 |
| Nogueira, ML | 1 |
| Suarez-Fontes, AM | 1 |
| Neves da Costa, JB | 1 |
| Rios-Santos, F | 1 |
| Vannier-Santos, MA | 1 |
| Huang, X | 1 |
| Kilgore, JA | 1 |
| Bair, JS | 1 |
| Parkinson, EI | 1 |
| Wang, Y | 1 |
| Williams, NS | 1 |
| Hergenrother, PJ | 1 |
| Sun, X | 1 |
| Li, Y | 1 |
| Li, W | 1 |
| Zhang, B | 1 |
| Wang, AJ | 1 |
| Sun, J | 1 |
| Mikule, K | 1 |
| Jiang, Z | 1 |
| Li, CJ | 2 |
| Li, YZ | 1 |
| Pinto, AV | 1 |
| Pardee, AB | 1 |
| Kumi-Diaka, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors[NCT01502800] | Phase 1 | 91 participants (Actual) | Interventional | 2011-12-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for beta-lapachone and Necrosis
| Article | Year |
|---|---|
Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.
Topics: Animals; Disease Models, Animal; DNA Repair; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Molecul | 2014 |
1 trial available for beta-lapachone and Necrosis
| Article | Year |
|---|---|
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; DNA Damage; Female; Humans; Male; Middl | 2018 |
7 other studies available for beta-lapachone and Necrosis
| Article | Year |
|---|---|
Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Topics: Breast Neoplasms; Catalase; DNA Breaks, Single-Stranded; DNA Damage; Female; Gene Expression Regulat | 2013 |
β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.
Topics: Antineoplastic Agents; Apoptosis Inducing Factor; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose- | 2014 |
Effects of a novel β-lapachone derivative on Trypanosoma cruzi: Parasite death involving apoptosis, autophagy and necrosis.
Topics: Apoptosis; Autophagy; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Naphthoqui | 2016 |
An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Calcium; Cell Line, Tumor; DNA Damage; Egtazic Acid; | 2012 |
Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Damage; Female; HeLa Cells; Humans; Mice; Mice | 2006 |
Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Carcinoma; Caspase 3; Caspases; Cell Death; Cytochrome c Gro | 1999 |
Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Apoptosis; Cell Division; Drug Synergism; Drug Therapy, | 2002 |